- call +1-201-465-4211
- email sales@mrinsights.biz
Scope of the Report:
The global Targeted Drugs for Multiple Myeloma market is valued at xx million USD in 2018 and is expected to reach xx million USD by the end of 2024, growing at a CAGR of xx% between 2019 and 2024.
The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Targeted Drugs for Multiple Myeloma.
Europe also play important roles in global market, with market size of xx million USD in 2019 and will be xx million USD in 2024, with a CAGR of xx%.
This report studies the Targeted Drugs for Multiple Myeloma market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Targeted Drugs for Multiple Myeloma market by product type and applications/end industries.
Market Segment by Companies, this report covers
Celgene
SL Pharma
Natco Pharma
Intas Pharmaceuticals
Indiabulls Pharmaceutical
Cipla
Glenmark Pharmaceuticals
Dr Reddy's Laboratories
Qilu Pharmaceutical
Chia Tai-Tianqing
Hanson Pharm
Meidakang Huakang Pharmaceutical
Shandong Kongfu Pharmaceutical
J&J
Takeda
Amgen
Bristol Myers Squibb
Abbvie
Seattle Genetics
Karyopharm Therapeutics
PDL BioPharma
Roche
Sumitomo
Merck
Biogen
Schering-Plough
Glaxo
Chiron
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Immunomodulator
Proteasome Inhibitors
Histone Deacetylase Inhibitors (HDACI)
Monoclonal Antibody
Other
Market Segment by Applications, can be divided into
Hospital
Drug Center
Clinic
Other
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
Table of Contents
1 Targeted Drugs for Multiple Myeloma Market Overview
1.1 Product Overview and Scope of Targeted Drugs for Multiple Myeloma
1.2 Classification of Targeted Drugs for Multiple Myeloma by Types
1.2.1 Global Targeted Drugs for Multiple Myeloma Revenue Comparison by Types (2019-2024)
1.2.2 Global Targeted Drugs for Multiple Myeloma Revenue Market Share by Types in 2018
1.2.3 Immunomodulator
1.2.4 Proteasome Inhibitors
1.2.5 Histone Deacetylase Inhibitors (HDACI)
1.2.6 Monoclonal Antibody
1.2.7 Other
1.3 Global Targeted Drugs for Multiple Myeloma Market by Application
1.3.1 Global Targeted Drugs for Multiple Myeloma Market Size and Market Share Comparison by Applications (2014-2024)
1.3.2 Hospital
1.3.3 Drug Center
1.3.4 Clinic
1.3.5 Other
1.4 Global Targeted Drugs for Multiple Myeloma Market by Regions
1.4.1 Global Targeted Drugs for Multiple Myeloma Market Size (Million USD) Comparison by Regions (2014-2024)
1.4.1 North America (USA, Canada and Mexico) Targeted Drugs for Multiple Myeloma Status and Prospect (2014-2024)
1.4.2 Europe (Germany, France, UK, Russia and Italy) Targeted Drugs for Multiple Myeloma Status and Prospect (2014-2024)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Targeted Drugs for Multiple Myeloma Status and Prospect (2014-2024)
1.4.4 South America (Brazil, Argentina, Colombia) Targeted Drugs for Multiple Myeloma Status and Prospect (2014-2024)
1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Targeted Drugs for Multiple Myeloma Status and Prospect (2014-2024)
1.5 Global Market Size of Targeted Drugs for Multiple Myeloma (2014-2024)
2 Manufacturers Profiles
2.1 Celgene
2.1.1 Business Overview
2.1.2 Targeted Drugs for Multiple Myeloma Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 Celgene Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
2.2 SL Pharma
2.2.1 Business Overview
2.2.2 Targeted Drugs for Multiple Myeloma Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 SL Pharma Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
2.3 Natco Pharma
2.3.1 Business Overview
2.3.2 Targeted Drugs for Multiple Myeloma Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 Natco Pharma Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
2.4 Intas Pharmaceuticals
2.4.1 Business Overview
2.4.2 Targeted Drugs for Multiple Myeloma Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 Intas Pharmaceuticals Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
2.5 Indiabulls Pharmaceutical
2.5.1 Business Overview
2.5.2 Targeted Drugs for Multiple Myeloma Type and Applications
2.5.2.1 Product A
2.5.2.2 Product B
2.5.3 Indiabulls Pharmaceutical Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
2.6 Cipla
2.6.1 Business Overview
2.6.2 Targeted Drugs for Multiple Myeloma Type and Applications
2.6.2.1 Product A
2.6.2.2 Product B
2.6.3 Cipla Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
2.7 Glenmark Pharmaceuticals
2.7.1 Business Overview
2.7.2 Targeted Drugs for Multiple Myeloma Type and Applications
2.7.2.1 Product A
2.7.2.2 Product B
2.7.3 Glenmark Pharmaceuticals Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
2.8 Dr Reddy's Laboratories
2.8.1 Business Overview
2.8.2 Targeted Drugs for Multiple Myeloma Type and Applications
2.8.2.1 Product A
2.8.2.2 Product B
2.8.3 Dr Reddy's Laboratories Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
2.9 Qilu Pharmaceutical
2.9.1 Business Overview
2.9.2 Targeted Drugs for Multiple Myeloma Type and Applications
2.9.2.1 Product A
2.9.2.2 Product B
2.9.3 Qilu Pharmaceutical Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
2.10 Chia Tai-Tianqing
2.10.1 Business Overview
2.10.2 Targeted Drugs for Multiple Myeloma Type and Applications
2.10.2.1 Product A
2.10.2.2 Product B
2.10.3 Chia Tai-Tianqing Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
2.11 Hanson Pharm
2.11.1 Business Overview
2.11.2 Targeted Drugs for Multiple Myeloma Type and Applications
2.11.2.1 Product A
2.11.2.2 Product B
2.11.3 Hanson Pharm Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
2.12 Meidakang Huakang Pharmaceutical
2.12.1 Business Overview
2.12.2 Targeted Drugs for Multiple Myeloma Type and Applications
2.12.2.1 Product A
2.12.2.2 Product B
2.12.3 Meidakang Huakang Pharmaceutical Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
2.13 Shandong Kongfu Pharmaceutical
2.13.1 Business Overview
2.13.2 Targeted Drugs for Multiple Myeloma Type and Applications
2.13.2.1 Product A
2.13.2.2 Product B
2.13.3 Shandong Kongfu Pharmaceutical Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
2.14 J&J
2.14.1 Business Overview
2.14.2 Targeted Drugs for Multiple Myeloma Type and Applications
2.14.2.1 Product A
2.14.2.2 Product B
2.14.3 J&J Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
2.15 Takeda
2.15.1 Business Overview
2.15.2 Targeted Drugs for Multiple Myeloma Type and Applications
2.15.2.1 Product A
2.15.2.2 Product B
2.15.3 Takeda Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
2.16 Amgen
2.16.1 Business Overview
2.16.2 Targeted Drugs for Multiple Myeloma Type and Applications
2.16.2.1 Product A
2.16.2.2 Product B
2.16.3 Amgen Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
2.17 Bristol Myers Squibb
2.17.1 Business Overview
2.17.2 Targeted Drugs for Multiple Myeloma Type and Applications
2.17.2.1 Product A
2.17.2.2 Product B
2.17.3 Bristol Myers Squibb Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
2.18 Abbvie
2.18.1 Business Overview
2.18.2 Targeted Drugs for Multiple Myeloma Type and Applications
2.18.2.1 Product A
2.18.2.2 Product B
2.18.3 Abbvie Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
2.19 Seattle Genetics
2.19.1 Business Overview
2.19.2 Targeted Drugs for Multiple Myeloma Type and Applications
2.19.2.1 Product A
2.19.2.2 Product B
2.19.3 Seattle Genetics Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
2.20 Karyopharm Therapeutics
2.20.1 Business Overview
2.20.2 Targeted Drugs for Multiple Myeloma Type and Applications
2.20.2.1 Product A
2.20.2.2 Product B
2.20.3 Karyopharm Therapeutics Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
2.21 PDL BioPharma
2.21.1 Business Overview
2.2.2 Targeted Drugs for Multiple Myeloma Type and Applications
2.21.2.1 Product A
2.21.2.2 Product B
2.21.3 PDL BioPharma Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
2.22 Roche
2.22.1 Business Overview
2.22.2 Targeted Drugs for Multiple Myeloma Type and Applications
2.22.2.1 Product A
2.22.2.2 Product B
2.22.3 Roche Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
2.23 Sumitomo
2.23.1 Business Overview
2.23.2 Targeted Drugs for Multiple Myeloma Type and Applications
2.23.2.1 Product A
2.23.2.2 Product B
2.23.3 Sumitomo Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
2.24 Merck
2.24.1 Business Overview
2.24.2 Targeted Drugs for Multiple Myeloma Type and Applications
2.24.2.1 Product A
2.24.2.2 Product B
2.24.3 Merck Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
2.25 Biogen
2.25.1 Business Overview
2.25.2 Targeted Drugs for Multiple Myeloma Type and Applications
2.25.2.1 Product A
2.25.2.2 Product B
2.25.3 Biogen Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
2.26 Schering-Plough
2.26.1 Business Overview
2.26.2 Targeted Drugs for Multiple Myeloma Type and Applications
2.26.2.1 Product A
2.26.2.2 Product B
2.26.3 Schering-Plough Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
2.27 Glaxo
2.27.1 Business Overview
2.27.2 Targeted Drugs for Multiple Myeloma Type and Applications
2.27.2.1 Product A
2.27.2.2 Product B
2.27.3 Glaxo Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
2.28 Chiron
2.28.1 Business Overview
2.28.2 Targeted Drugs for Multiple Myeloma Type and Applications
2.28.2.1 Product A
2.28.2.2 Product B
2.28.3 Chiron Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
3 Global Targeted Drugs for Multiple Myeloma Market Competition, by Players
3.1 Global Targeted Drugs for Multiple Myeloma Revenue and Share by Players (2014-2019)
3.2 Market Concentration Rate
3.2.1 Top 5 Targeted Drugs for Multiple Myeloma Players Market Share
3.2.2 Top 10 Targeted Drugs for Multiple Myeloma Players Market Share
3.3 Market Competition Trend
4 Global Targeted Drugs for Multiple Myeloma Market Size by Regions
4.1 Global Targeted Drugs for Multiple Myeloma Revenue and Market Share by Regions
4.2 North America Targeted Drugs for Multiple Myeloma Revenue and Growth Rate (2014-2019)
4.3 Europe Targeted Drugs for Multiple Myeloma Revenue and Growth Rate (2014-2019)
4.4 Asia-Pacific Targeted Drugs for Multiple Myeloma Revenue and Growth Rate (2014-2019)
4.5 South America Targeted Drugs for Multiple Myeloma Revenue and Growth Rate (2014-2019)
4.6 Middle East and Africa Targeted Drugs for Multiple Myeloma Revenue and Growth Rate (2014-2019)
5 North America Targeted Drugs for Multiple Myeloma Revenue by Countries
5.1 North America Targeted Drugs for Multiple Myeloma Revenue by Countries (2014-2019)
5.2 USA Targeted Drugs for Multiple Myeloma Revenue and Growth Rate (2014-2019)
5.3 Canada Targeted Drugs for Multiple Myeloma Revenue and Growth Rate (2014-2019)
5.4 Mexico Targeted Drugs for Multiple Myeloma Revenue and Growth Rate (2014-2019)
6 Europe Targeted Drugs for Multiple Myeloma Revenue by Countries
6.1 Europe Targeted Drugs for Multiple Myeloma Revenue by Countries (2014-2019)
6.2 Germany Targeted Drugs for Multiple Myeloma Revenue and Growth Rate (2014-2019)
6.3 UK Targeted Drugs for Multiple Myeloma Revenue and Growth Rate (2014-2019)
6.4 France Targeted Drugs for Multiple Myeloma Revenue and Growth Rate (2014-2019)
6.5 Russia Targeted Drugs for Multiple Myeloma Revenue and Growth Rate (2014-2019)
6.6 Italy Targeted Drugs for Multiple Myeloma Revenue and Growth Rate (2014-2019)
7 Asia-Pacific Targeted Drugs for Multiple Myeloma Revenue by Countries
7.1 Asia-Pacific Targeted Drugs for Multiple Myeloma Revenue by Countries (2014-2019)
7.2 China Targeted Drugs for Multiple Myeloma Revenue and Growth Rate (2014-2019)
7.3 Japan Targeted Drugs for Multiple Myeloma Revenue and Growth Rate (2014-2019)
7.4 Korea Targeted Drugs for Multiple Myeloma Revenue and Growth Rate (2014-2019)
7.5 India Targeted Drugs for Multiple Myeloma Revenue and Growth Rate (2014-2019)
7.6 Southeast Asia Targeted Drugs for Multiple Myeloma Revenue and Growth Rate (2014-2019)
8 South America Targeted Drugs for Multiple Myeloma Revenue by Countries
8.1 South America Targeted Drugs for Multiple Myeloma Revenue by Countries (2014-2019)
8.2 Brazil Targeted Drugs for Multiple Myeloma Revenue and Growth Rate (2014-2019)
8.3 Argentina Targeted Drugs for Multiple Myeloma Revenue and Growth Rate (2014-2019)
8.4 Colombia Targeted Drugs for Multiple Myeloma Revenue and Growth Rate (2014-2019)
9 Middle East and Africa Revenue Targeted Drugs for Multiple Myeloma by Countries
9.1 Middle East and Africa Targeted Drugs for Multiple Myeloma Revenue by Countries (2014-2019)
9.2 Saudi Arabia Targeted Drugs for Multiple Myeloma Revenue and Growth Rate (2014-2019)
9.3 UAE Targeted Drugs for Multiple Myeloma Revenue and Growth Rate (2014-2019)
9.4 Egypt Targeted Drugs for Multiple Myeloma Revenue and Growth Rate (2014-2019)
9.5 Nigeria Targeted Drugs for Multiple Myeloma Revenue and Growth Rate (2014-2019)
9.6 South Africa Targeted Drugs for Multiple Myeloma Revenue and Growth Rate (2014-2019)
10 Global Targeted Drugs for Multiple Myeloma Market Segment by Type
10.1 Global Targeted Drugs for Multiple Myeloma Revenue and Market Share by Type (2014-2019)
10.2 Global Targeted Drugs for Multiple Myeloma Market Forecast by Type (2019-2024)
10.3 Immunomodulator Revenue Growth Rate (2014-2024)
10.4 Proteasome Inhibitors Revenue Growth Rate (2014-2024)
10.5 Histone Deacetylase Inhibitors (HDACI) Revenue Growth Rate (2014-2024)
10.6 Monoclonal Antibody Revenue Growth Rate (2014-2024)
10.7 Other Revenue Growth Rate (2014-2024)
11 Global Targeted Drugs for Multiple Myeloma Market Segment by Application
11.1 Global Targeted Drugs for Multiple Myeloma Revenue Market Share by Application (2014-2019)
11.2 Targeted Drugs for Multiple Myeloma Market Forecast by Application (2019-2024)
11.3 Hospital Revenue Growth (2014-2019)
11.4 Drug Center Revenue Growth (2014-2019)
11.5 Clinic Revenue Growth (2014-2019)
11.6 Other Revenue Growth (2014-2019)
12 Global Targeted Drugs for Multiple Myeloma Market Size Forecast (2019-2024)
12.1 Global Targeted Drugs for Multiple Myeloma Market Size Forecast (2019-2024)
12.2 Global Targeted Drugs for Multiple Myeloma Market Forecast by Regions (2019-2024)
12.3 North America Targeted Drugs for Multiple Myeloma Revenue Market Forecast (2019-2024)
12.4 Europe Targeted Drugs for Multiple Myeloma Revenue Market Forecast (2019-2024)
12.5 Asia-Pacific Targeted Drugs for Multiple Myeloma Revenue Market Forecast (2019-2024)
12.6 South America Targeted Drugs for Multiple Myeloma Revenue Market Forecast (2019-2024)
12.7 Middle East and Africa Targeted Drugs for Multiple Myeloma Revenue Market Forecast (2019-2024)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
List of Tables and Figures
Figure Targeted Drugs for Multiple Myeloma Picture
Table Product Specifications of Targeted Drugs for Multiple Myeloma
Table Global Targeted Drugs for Multiple Myeloma and
ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems
Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system
Global Outreach6 Major regions and 40+ countries level analysis accomplished
Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery
